The Science
Everything we say about Akkermansia traces back to a published study. Here is the evidence — read it yourself.
What Akkermansia muciniphila is
A gut bacterium first described in 2004, named for the mucus layer it lives in and feeds on. Over two decades it has become one of the most-studied microbes in metabolic and longevity research, with its own reviews in Nature Reviews Gastroenterology & Hepatology and Nature Reviews Microbiology.
The mucin layer
Your gut wall is protected by two layers of mucus. Akkermansia lives in the outer layer and, as it grazes on mucin, signals your own cells to produce more — and a well-maintained mucus layer is associated with a stronger gut barrier. That single relationship runs through most of the research below.
Three pillars
Metabolic
Insulin sensitivity, the GLP-1 pathway, and the polyphenol–microbiome link. Anchors our Bilberry pairing.
Longevity
Pomegranate, urolithin A, and mitochondrial health. Anchors our Pomegranate pairing.
Gut
The mucin layer, the gut barrier, and microbial diversity. Anchors our Raspberry pairing.
The evidence
Landmark studies, with the model and the source. Most of this research is in cells and animals; the human evidence is real but still early. We describe what each study found — we do not promise you the same result.
| Finding | Model | Source |
|---|---|---|
| Mechanism Discovery and naming of Akkermansia muciniphila as a mucin-degrading bacterium of the human gut. | review | Derrien M et al. Int J Syst Evol Microbiol 2004. DOI · PubMed |
| Metabolic Identified a cross-talk between Akkermansia and the gut lining that influences diet-induced obesity in mice. | mouse | Everard A et al. PNAS 2013. DOI · PubMed |
| Metabolic Cranberry polyphenols increased Akkermansia abundance and improved metabolic markers in mice — a clean berry-polyphenol → Akkermansia chain. | mouse | Anhê FF et al. Gut 2015. DOI · PubMed |
| Longevity Urolithin A induced mitophagy and prolonged lifespan in C. elegans, and improved muscle function in rodents. | C. elegans / rodent | Ryu D et al. Nat Med 2016. DOI · PubMed |
| Mechanism A purified surface protein — and the pasteurised bacterium — reproduced metabolic effects in obese and diabetic mice. | mouse | Plovier H et al. Nat Med 2017. DOI · PubMed |
| Longevity Pomegranate ellagitannins stimulated the growth of Akkermansia muciniphila in vivo (mice). | mouse | Henning SM et al. Anaerobe 2017. DOI · PubMed |
| Metabolic Blueberry supplementation influenced gut microbiota, inflammation and insulin resistance in a human study. | human study | Lee S et al. J Nutr 2018. DOI · PubMed |
| Longevity First human trial of urolithin A: safe, with a molecular signature of improved mitochondrial and cellular health (n=60). | human RCT | Andreux PA et al. Nat Metab 2019. DOI · PubMed |
| Gut Urolithin A supported gut-barrier integrity via the Nrf2 pathway. | in vitro / mouse | Singh R et al. Nat Commun 2019. DOI · PubMed |
| Metabolic First human trial of Akkermansia: the pasteurised form was safe and associated with improved metabolic markers over three months (n=32). | human RCT | Depommier C et al. Nat Med 2019. DOI · PubMed |
| Metabolic Identified P9, a protein Akkermansia secretes that triggers GLP-1 release from gut L-cells via the ICAM-2 receptor (mouse). | in vitro / mouse | Yoon HS et al. Nat Microbiol 2021. DOI · PubMed |
| Mechanism Comprehensive review positioning Akkermansia as a paradigm next-generation beneficial microbe. | review | Cani PD et al. Nat Rev Gastroenterol Hepatol 2022. DOI · PubMed |
| Longevity Randomised trial: urolithin A improved muscle endurance and mitochondrial biomarkers in middle-aged adults (n=88). | human RCT | Singh A et al. Cell Rep Med 2022. DOI · PubMed |
| Longevity Systematic review of the growing human evidence base for urolithin A. | review | Kuerec AH et al. Ageing Res Rev 2024. DOI · PubMed |
| Mechanism 2025 Nature Reviews Microbiology review of Akkermansia biology, ecology and therapeutic potential. | review | Ioannou A et al. Nat Rev Microbiol 2025. DOI · PubMed |
| Metabolic Human trial extending Akkermansia research into people with type 2 diabetes. | human RCT | Zhang Y et al. Cell Metab 2025. DOI · PubMed |
How we cite
We link every claim to a primary source you can open. We do not use 'on-hold' botanical claims, and we make no claim that Vekovia treats, prevents or cures anything. When the science is preliminary, we say so.